TAR-210 not checked

Johnson & Johnson (Janssen) · JNJ-42756493

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Non-Muscle Invasive Bladder Neoplasms (2 trials)
Main trialPhase 3
“The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Guérin (BCG) treated participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC).”In the company’s words, NCT06919965 on ClinicalTrials.gov
Other names
JNJ-42756493

Other drugs for Non-Muscle Invasive Bladder Neoplasms

All 26 drugs for Non-Muscle Invasive Bladder Neoplasms

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 6 Apr 2028 A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Phase 3Recruiting 28 Jun 2028 A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TAR-210

Following is part of Solo: you see every change to TAR-210 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in